Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (4401)	1/7/1998 8:45:00 PM
From: LoLoLoLita	Respond to of 23519

>>Q: What product launches will we see from Pfizer in 1998? >>A: We expect several major launches next year. The first >>launch will be our broad-spectrum antibiotic Trovan. >>Second launch should be Viagra. The FDA put it on >>fast-track review. So that means we could get approval >>at the end of the first quarter. "should ... could" sounds kind of iffy to me

To: BigKNY3 who wrote (4401)	1/7/1998 11:27:00 PM
From: EyeDrMike	Read Replies (1) \| Respond to of 23519

"Q: What product launches will we see from Pfizer in 1998? A: We expect several major launches next year. The first launch will be our broad-spectrum antibiotic Trovan. Second launch should be Viagra. The FDA put it on fast-track review. So that means we could get approval at the end of the first quarter."" seems to me "could" is a far cry from approval; and i listen to rumors; part of evaluating a company just like anything else. And from what i've read, end of first Q is not even a remote possibility. Mike